Malvern, PA, April 4, 2016 — PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and leader in the field of biopolymer-based drugs, focused on developing treatments for metabolic and specialty cardiopulmonary disorders, today announced that Chief Executive Officer Jonathan P. Mow will present a company overview at Needham & Company’s 15th Annual Healthcare Conference, on Wednesday, April 13, at 3 p.m. EDT at the Westin New York Grand Central Hotel in New York City.

For additional information on the conference, please visit: http://www.needhamco.com/Default/InstitutionalSalesAndTrading/Conferences.aspx.

About PhaseBio

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel drugs to treat metabolic and specialty cardiopulmonary disorders. The Company’s proprietary technology platform uses recombinant elastin-like polypeptide (ELP) biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The resulting compounds are engineered for a specific rate of absorption to enhance efficacy and reduce side effects. PhaseBio’s lead development candidates include: PE0139, a novel, super-long-acting basal insulin-ELP fusion for once-weekly dosing; and PB1046, a weekly vasoactive intestinal peptide receptor agonist for the treatment of acute and chronic heart failure, the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, Becker muscular dystrophy and X-linked dilated cardiomyopathy, and other indications. PhaseBio is privately owned with headquarters and research laboratories in Malvern, Pa.

 


 

Media Contact:
Laura Bagby, 6 Degrees
(312) 448-8098
lbagby@6degreespr.com